Stanford wants Secukinumab trialists

Written by on August 5, 2017 in clinical trials, research with 0 Comments

A clinical trial at Stanford Dermatology is seeking trialists to join a study looking at Secukinumab as a treatment for the papules and pustules, and redness associated with rosacea. If you are interested, and meet the requirements for the trial, please contact them via their details below.

What is Secukinumab?

Secukinumab (brand name Cosentyx) has recently become a FDA approved treatment for psoriasis. From the clinical trial description –

Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) that is involved in inflammation. When IL-17A is bound to secukinumab, it cannot bind to its receptor, thereby inhibiting its ability to feed the inflammatory response.

In clinical trials, secukinumab has been effective for moderate to severe psoriasis (Blauvelt et al., 2015). Recently, human data from all types of rosacea have shown Th1/Th17 polarization profile of the T-cell response, suggesting that anti-IL-17 therapy may be beneficial for rosacea (Buhl et al., 2015).

Hence, secukinumab could be effective against rosacea. This proposal is a proof-of-concept study to use secukinumab in open label design for moderate to severe papulopustular rosacea.

Please Contact Stanford Dermatology Directly

Are you suffering from rosacea? Join our study to help find a new treatment for your rosacea. Requirements for study participation:

  •  Clinical diagnosis of rosacea (at least 10 bumps with redness)
  •  Age ≥ 18
  • Monthly visits
  • Willing to use weekly to monthly self-injectable medication, secukinumab, a drug that is FDA approved for another skin condition.
Please call (650) 721-7159 for more information.
Stanford Dermatology Outpatient Clinic
450 Broadway, MC5334
Stanford, CA 94603

Clinical Trial NCT03079531

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

Outcome Measures:

  • number of papules/pustules on rosacea patients at week 16 vs 0
  • reduction in the number of papules and/or pustules in moderate to severe papulopustular rosacea at week 12 vs 0
  • reduction of the overall severity of rosacea by global assessment
  • reduction of erythema in patients with moderate to severe papulopustular rosacea
  • improved quality of life measures in patients with moderate to severe papulopustular rosacea
  • assess adverse events ≥ grade 3 in patients taking secukinumab for moderate to severe papulopustular rosacea
  • changes in immune infiltrate in papulopustular rosacea lesions after secukinumab use
Estimated Enrollment:24
Anticipated Study Start Date:July 14, 2017
Estimated Study Completion Date:January 1, 2019


Related Articles

Read more about: clinical trials, research

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.